Treace Medical Concepts, Inc
Treace Medical Concepts is a U.S.-based medical device company focused on surgical systems for bunion and midfoot correction. Its core offering centers on the Lapiplasty System and related implant kits, single-use instruments, reusable trays, and procedure-specific tools used by foot and ankle surgeons.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueProcedure-specific systems for Lapidus-style bunion correction and related foot surgery.
Products and instruments used in multi-joint TMT fusion and related procedures.
Disposable sterile instruments, implant kits, and complementary consumables.
Clinical education, surgeon outreach, and patient-facing support tools.
Customers
Treace sells primarily to surgeons and surgical facilities that perform bunion and midfoot procedures, including hospitals, ambulatory surgery centers, and stocking distributors. The company also supports physician adoption through training and patient education, which is important because its products are tied to a specific surgical technique and require surgeon familiarity.
Surgical podiatrists and orthopaedic foot-and-ankle surgeons who buy the systems to perform bunion correction procedures.
Facilities that purchase or approve the systems for outpatient and inpatient procedures, often through contract and reimbursement frameworks.
Outpatient centers that use the systems for elective bunion and midfoot procedures where workflow and reimbursement matter.
Intermediaries that stock and resell products to facilities, extending reach but often with longer payment terms.
End users of the procedures whose awareness and surgeon selection are influenced by direct-to-patient education.
Strategy
Treace’s strategy is to expand adoption of its bunion correction platform by training more surgeons, increasing utilization per physician, and broadening its product set. It also aims to defend and extend its position through product innovation, commercialization of PSI technologies, and selective expansion into minimally invasive osteotomy and other adjacent foot-and-ankle opportunities.
The business depends on surgeon familiarity and procedural adoption to drive recurring system use.
Additional products can increase procedure coverage and reduce dependence on one flagship system.
Bundling and contract leverage from larger device companies can limit access to customers.
Adjacent indications can enlarge the addressable market beyond bunion correction.
Geography
Treace’s business is concentrated in the United States, where it markets and sells through a direct employee sales force and independent sales agencies. The company’s procedures are performed in U.S. hospital outpatient departments and ambulatory surgery centers, and its commercial model is built around domestic surgeon training, reimbursement, and facility access.
Risks
Treace faces concentrated product and market risk because a large share of its business depends on Lapiplasty adoption in a competitive orthopedic foot-and-ankle market. Its exposure to hospital and IDN purchasing behavior, reimbursement dynamics, physician relationships, and regulatory scrutiny can affect access, pricing, and growth.
- Competitive bundling and rebate pressureImpact: HighLikelihood: High
Large device companies can use broader product portfolios to win accounts and displace Treace products.
Exposure - Dependence on a single flagship productImpact: HighLikelihood: Medium
A large portion of revenue comes from Lapiplasty, so slower adoption or substitution would directly affect sales.
Exposure: Lapiplasty System
- Reimbursement and access riskImpact: HighLikelihood: Medium
If payors or facilities change coverage or pricing, surgeons may use the procedures less often.
Exposure: Hospital outpatient and ASC procedures
- Regulatory and compliance riskImpact: MediumLikelihood: Medium
Medical device relationships with physicians are subject to fraud, abuse, and transparency laws.
Exposure - Seasonality and elective surgery sensitivityImpact: MediumLikelihood: Medium
Bunion procedures are elective and volumes can vary by quarter and broader consumer conditions.
Exposure: Fourth-quarter and first-quarter sales
Accounting
Judgemental itemsRevenue depends on shipment/sale timing for implant kits, instruments, and related products.
Impact: Affects quarter-to-quarter comparability
Fourth-quarter sales are typically stronger and first-quarter sales weaker, distorting trend analysis.
Impact: Impacts quarterly revenue and margin comparisons
Fair value estimates for options and PSUs affect operating expenses and dilution-related analysis.
Impact: Non-cash expense can be material
Goodwill is tested annually and could be written down if expected cash flows weaken.
Impact: Could create a non-cash charge
Headquarters lease and sublease obligations affect liabilities and expense recognition.
Impact: Impacts balance sheet and cash commitments
Similar listed companies
Publicly listed companies with a comparable business focus.
Tenon Medical, Inc.
TNONW · Surgical & Medical Instruments & Apparatus
SI-BONE, Inc.
SIBN · Surgical & Medical Instruments & Apparatus
Tactile Systems Technology, Inc
TCMD · Surgical & Medical Instruments & Apparatus
Tactile Systems Technology is a U.S.-based medical technology company that develops and sells home-based devices for chronic disease management.
Sanara MedTech Inc.
SMTI · Orthopedic, Prosthetic & Surgical Appliances & Supplies
ENvue Medical, Inc.
FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Teleflex Incorporated
TFX · Surgical & Medical Instruments & Apparatus
Last updated: 24/09/2026